Basit öğe kaydını göster

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

dc.contributor.authorMcNeely, Samuel
dc.contributor.authorForster, Martin
dc.contributor.authorWang, Xuejing
dc.contributor.authorHynes, Scott
dc.contributor.authorLin, Aimee Bence
dc.contributor.authorByers, Lauren Averett
dc.contributor.authorNavarro, Alejandro
dc.contributor.authorSchaefer, Eric
dc.contributor.authorJohnson, Melissa
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorHan, Ji-Youn
dc.contributor.authorBondarenko, Igor
dc.contributor.authorÇİÇİN, İRFAN
dc.contributor.authorDragnev, Konstantin H.
dc.contributor.authorAbel, Adam
dc.date.accessioned2022-02-18T10:36:45Z
dc.date.available2022-02-18T10:36:45Z
dc.date.issued2021
dc.identifier.citationByers L. A. , Navarro A., Schaefer E., Johnson M., Ozguroglu M., Han J., Bondarenko I., ÇİÇİN İ., Dragnev K. H. , Abel A., et al., "A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer", CLINICAL LUNG CANCER, cilt.22, sa.6, ss.531-540, 2021
dc.identifier.issn1525-7304
dc.identifier.othervv_1032021
dc.identifier.otherav_ac5736cb-2ec3-45ec-ad75-3eee15f55353
dc.identifier.urihttp://hdl.handle.net/20.500.12627/179568
dc.identifier.urihttps://doi.org/10.1016/j.cllc.2021.04.005
dc.description.abstractPatients with extensive-stage small-cell lung cancer (ED-SCLC) need improved outcomes in the relapsed/refractory setting. This phase II study evaluated the safety and efficacy of prexasertib, a checkpoint kinase 1 inhibitor, in platinum-sensitive and platinum-refractory ED-SCLC. Prexasertib demonstrated response rates of 5.2% in platinum-sensitive and 0% in platinum-refractory ED-SCLC. Prexasertib did not show prespecified efficacy as monotherapy in ED-SCLC.
dc.language.isoeng
dc.subjectOncology
dc.subjectHealth Sciences
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.subjectOnkoloji
dc.titleA Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer
dc.typeMakale
dc.relation.journalCLINICAL LUNG CANCER
dc.contributor.departmentUniversity of Texas System , ,
dc.identifier.volume22
dc.identifier.issue6
dc.identifier.startpage531
dc.identifier.endpage540
dc.contributor.firstauthorID2773315


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster